-
41
Targeting murine metastatic cancers with cholera toxin A1-adjuvanted peptide vaccines
Published 2025-12-01“…Human Vaccines & Immunotherapeutics…”
Get full text
Article -
42
Adverse events following immunization surveillance on two types of enterovirus 71 vaccines: A real-world comparative study in China
Published 2025-12-01“…Human Vaccines & Immunotherapeutics…”
Get full text
Article -
43
Analysis of a case of pilomatricoma in an adolescent after receiving recombinant hepatitis B vaccine (CHO cell) in Beijing of China
Published 2025-12-01“…Human Vaccines & Immunotherapeutics…”
Get full text
Article -
44
Understanding barriers to influenza vaccination among parents is important to improve vaccine uptake among children
Published 2025-12-01“…Human Vaccines & Immunotherapeutics…”
Get full text
Article -
45
Strategies for introducing and implementing vaccines for adults into national immunization programs in Europe: Good practices and key insights of the adult immunization board meeti...
Published 2025-12-01“…Human Vaccines & Immunotherapeutics…”
Get full text
Article -
46
Pembrolizumab- induced subacute cutaneous lupus erythematosus in a patient with oropharyngeal squamous cell carcinoma: A case report and literature review
Published 2025-12-01“…Human Vaccines & Immunotherapeutics…”
Get full text
Article -
47
Research trends of neoadjuvant therapy for breast cancer: A bibliometric analysis
Published 2025-12-01“…Human Vaccines & Immunotherapeutics…”
Get full text
Article -
48
Surveillance on the coverage of herpes zoster vaccine and post-marketing adverse events in Jiangsu province, China
Published 2025-12-01“…Human Vaccines & Immunotherapeutics…”
Get full text
Article -
49
Acceptance and attitudes towards COVID-19 vaccination during pregnancy in Canada
Published 2025-12-01“…Human Vaccines & Immunotherapeutics…”
Get full text
Article -
50
PfCSP-ferritin nanoparticle malaria vaccine antigen formulated with aluminum-salt and CpG 1018® adjuvants: Preformulation characterization, antigen-adjuvant interactions, and mouse...
Published 2025-12-01“…Human Vaccines & Immunotherapeutics…”
Get full text
Article -
51
Vaccine effectiveness against influenza-associated hospitalizations in adults with liver disease, 2015–2020: US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN)...
Published 2025-12-01“…Human Vaccines & Immunotherapeutics…”
Get full text
Article -
52
Modifying non-coding regions of linear DNA vaccines to explore the interplay of expression and inflammation in immunogenicity
Published 2025-12-01“…Human Vaccines & Immunotherapeutics…”
Get full text
Article -
53
Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy
Published 2025-12-01“…Human Vaccines & Immunotherapeutics…”
Get full text
Article -
54
Neoantigen mRNA vaccines and A2A receptor antagonism: A strategy to enhance T cell immunity
Published 2025-12-01“…Human Vaccines & Immunotherapeutics…”
Get full text
Article -
55
Global research hotspots and trends in DNA vaccine research: A bibliometric and visualization study from 2014 to 2024
Published 2025-12-01“…Human Vaccines & Immunotherapeutics…”
Get full text
Article -
56
Pneumococcal vaccination in elderly care facilities in Japan: A cross-sectional, web-based survey
Published 2025-12-01“…Human Vaccines & Immunotherapeutics…”
Get full text
Article -
57
Opportunities and challenges of immuno-oncology: A bibliometric analysis from 2014 to 2023
Published 2025-12-01“…Human Vaccines & Immunotherapeutics…”
Get full text
Article -
58
Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza in elderly Chinese patients with diabetes: A test-negative design case-control study
Published 2025-12-01“…Human Vaccines & Immunotherapeutics…”
Get full text
Article -
59
Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy
Published 2025-12-01“…Human Vaccines & Immunotherapeutics…”
Get full text
Article -
60
Immunogenicity and safety of a live attenuated varicella vaccine in children aged 1 to 12 years: A double-blind, randomized, parallel-controlled phase III clinical trial in China
Published 2025-12-01“…Human Vaccines & Immunotherapeutics…”
Get full text
Article